Autopsy report · NCT04968379

Safety, Tolerability, PK and PD of Intravenous Ferric Carboxymaltose in Infants With Iron Deficiency Anemia

“Difficult to recruit and enroll patients for this study in a reasonable amount of time.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

American Regent, Inc.

Sponsor type

Industry

Conditions

Iron Deficiency, Anaemia

Interventions

Ferric carboxymaltose

Participants

0

Sites

4

Countries

United States

Trials that died the same way

• IL-6 and IL-8 Level of Blood and Pleural Effusion During Chemotherapy in Metastatic Breast Cancer
  “it's too slow to enroll suitable patients into this study” (82% match in meaning)
• Cooling the Uterus in C-section After Dysfunctional Labor
  “Difficulty in acquiring patients in a reasonable amount of time.” (82% match in meaning)
• Platelet Function With New Pediatric Oxygenator and Heparin and Non Heparin Coating in Pediatric Cardiac Surgery
  “for difficulty to enroll patients in the study” (80% match in meaning)
• Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy
  “difficult to recruit patients” (75% match in meaning)
• Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease
  “due to the difficulty to enroll suitable patients” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.